GlaxoSmithKline (GSK) has acquired all outstanding shares of Canadian biopharmaceutical firm Bellus Health for a total equity price of $2bn or $14.75 for each share in cash.
30 Jun 2023
15 Mar 2023
China National Medical Products Administration has accepted the review of GSK’s drug application for Nucala (mepolizumab) as an add-on maintenance treatment for severe eosinophilic asthma (SEA).
11 Jan 2023
ReCode Therapeutics has announced that it will secure a strategic investment from the Cystic Fibrosis Foundation (CF Foundation) to develop its inhaled mRNA-based therapeutic for cystic fibrosis (CF).
10 Nov 2022
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has given approval to Beyfortus (nirsevimab) to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season.
26 Jul 2022
AstraZeneca’s Tezspire (tezepelumab) has been recommended for marketing authorisation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency as an add-on therapy in patients aged 12 years and above suffering with severe asthma.
21 Jun 2022
China-based biotech company Therorna has secured $42m in a Series A financing round to support its growth and fuel product pipeline development.
25 Feb 2022
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Boehringer Ingelheim’s new oral therapy, BI 1015550, to treat patients with idiopathic pulmonary fibrosis (IPF).
23 Dec 2021
Pfizer has signed an agreement to deliver an additional 2.5 million treatment courses of its investigational Covid-19 pill Paxlovid to the UK.
02 Sep 2021
Merck and Ridgeback Biotherapeutics have initiated a Phase III clinical trial to evaluate investigational oral antiviral therapeutic molnupiravir to prevent Covid-19 infection.
23 Mar 2021
US-based global biotechnology company Dyadic International has announced the expansion of its partnership with South Korea-based global research biopharmaceutical company Medytox to co-develop C1 manufactured Covid-19 vaccines.